View Full Version : FDA approves Novo Nordisk's injection for obesity

12-25-14, 09:56 AM
Natalie Grover
Tue Dec 23, 2014

(Reuters) - The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans.

The injectable drug, to be marketed as Saxenda, is the second obesity treatment to be approved this year after Orexigen Therapeutics Inc's oral medication Contrave in September.

Saxenda enters a market that is yet to realize its potential due to limited effectiveness of existing drugs, reimbursement hurdles, bungled launches and the perception of obesity as a 'lifestyle' disease.

The drug has been approved for patients with a body mass index of 30 or above and at least one weight-related health condition such as diabetes, the U.S. Food and Drug Administration said on Tuesday.

Read more: http://www.reuters.com/article/2014/12/23/us-novo-nordisk-obesity-fda-idUSKBN0K11TU20141223?feedType=RSS&feedName=healthNews